Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Rosebank to buy US firm in $1.9bn deal

(Sharecast News) - Rosebank is to raise more than £1bn to acquire US-based Electrical Components International, the British investment firm said on Friday. Under the terms of the deal, Rosebank will acquire ECI - an electrical components specialist founded in 1953 - for an enterprise value of around $1.9bn on a debt and cash free basis, nine times expected 2025 adjusted EBITDA.

It will fund the acquisition through debt facilities and a fully underwritten institutional capital raise priced at 300p per share, which is expected to raise £1.14bn.

The deal is Rosebank's first since it floated on Aim last year. The business was founded by veteran dealmaker Simon Peckham with a specific 'buy, improve and sell' focus.

Rosebank said "numerous" other acquisition targets had also been identified, adding: "M&A opportunities general, and for ECI, are enhanced by the turbulence of recent months."

Peckham said: "This is the first step on the journey and we are very confident we can help ECI to fully realise its potential, for the benefit of its employees, customers and our shareholders."

Russ Mould, investment director at AJ Bell, said: "Share in the cash shell rocketed on the stock market debut last summer, as investors speculated about what Rosebank might achieve.

"Reality now hits hard that it will need to raise a significant amount of money to make acquisitions, and then I could year to do each one up.

"Rosebank is certainly not buying ECI on the cheap. It is paying nine times adjusted earnings, which is fine for a company that is running smoothly but twice as much as you might find with acquisitions of a broken business.

"Rosebank hopes to improve ECI's margins, improve working capital and reduce leverage, so servicing debt doesn't consumer so much of its cashflow. This sounds like fine tuning the engine rather than chucking in a new one."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.